The Hybrid Closed-Loop System: Evolution and Practical Applications
Authors:
Open Access
- 1 June 2018
- journal article
- research article
- Published by SAGE Publications in Diabetes Technology & Therapeutics
- Vol. 20 (2_suppl) , 16-23
Abstract
Achievement of well-controlled blood glucose is essential for preventing complications in patients with type 1 diabetes. Since the inception of continuous subcutaneous insulin infusion, the aim has been to develop an artificial pancreas, with the ability to use an automated algorithm to deliver one or more hormones in response to blood glucose with the intent to keep blood sugar as close to a prespecified target as possible. Development and rapid improvement of continuous glucose sensor technology has recently allowed swift progress toward a fully closed-loop insulin delivery system. In 2017, Medtronic began marketing the 670G insulin pump with Guardian 3 sensor. When in auto mode, this is a hybrid closed-loop insulin delivery system that automatically adjusts basal insulin delivery every 5 min based on sensor glucose to maintain blood glucose levels as close to a specific target as possible. Patients receive prandial insulin by entering carbohydrate amount into the bolus calculator. Early studies show improvement in HbA1c in both adults and adolescents with this technology. Initial safety trials showed no occurrence of diabetic ketoacidosis or hypoglycemia. The utility of this device is limited by blood glucose targets of 120 and 150 mg/dL that are unacceptably high for some patients. Notwithstanding recent advances, we are far from a system that is able to replicate islet function in the form of a fully automated, multihormonal blood glucose control device.Keywords
This publication has 27 references indexed in Scilit:
- Safety of a Hybrid Closed-Loop Insulin Delivery System in Patients With Type 1 DiabetesJAMA, 2016
- Safety of Outpatient Closed-Loop Control: First Randomized Crossover Trials of a Wearable Artificial PancreasDiabetes Care, 2014
- Nocturnal Glucose Control with an Artificial Pancreas at a Diabetes CampNew England Journal of Medicine, 2013
- Multinational Study of Subcutaneous Model-Predictive Closed-Loop Control in Type 1 Diabetes Mellitus: Summary of the ResultsJournal of Diabetes Science and Technology, 2010
- Fully Automated Closed-Loop Insulin Delivery Versus Semiautomated Hybrid Control in Pediatric Patients With Type 1 Diabetes Using an Artificial PancreasDiabetes Care, 2008
- Continuous Glucose MonitoringDiabetes Care, 2005
- Control of Blood Sugar in Insulin-Dependent Diabetes: Comparison of an Artificial Endocrine Pancreas, Continuous Subcutaneous Insulin Infusion, and Intensified Conventional Insulin TherapyNew England Journal of Medicine, 1980
- Reduction to Normal of Plasma Glucose in Juvenile Diabetes by Subcutaneous Administration of Insulin with a Portable Infusion PumpNew England Journal of Medicine, 1979
- Continuous subcutaneous insulin infusion: an approach to achieving normoglycaemia.BMJ, 1978
- Clinical Control of Diabetes by the Artificial PancreasDiabetes, 1974